Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial

Eupraxia Pharmaceuticals (EPRX) announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for the treatment of eosinophilic esophagitis, EoE. At 36 weeks, patients in Cohort 9 demonstrated a “robust” response in both tissue health and symptom response compared to their baseline levels. Patients in Cohort 9 also demonstrated the highest response in tissue health at week 36 compared to all other dose cohorts in the Resolve trial. Clinical remission in symptoms was maintained in 66% of the patients in Cohort 9 at week 36. This level of remission was first achieved at week 8 and was maintained through 36 weeks. EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase 1b/2a study and over 230 patient-months of follow-up have been reported with no drug related Serious Adverse Events. There still have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids.